Please use this identifier to cite or link to this item: https://hdl.handle.net/10419/319149 
Year of Publication: 
2025
Series/Report no.: 
IZA Discussion Papers No. 17880
Publisher: 
Institute of Labor Economics (IZA), Bonn
Abstract: 
The 340B Drug Pricing Program was instituted to bolster the health care safety net without relying on taxpayer money. It allows participating health care facilities – most of which are hospitals – to purchase drugs filled at in-house or contracted external pharmacies at discounts from manufacturers. Hospitals argue that these discounts are critical to their provision of charity care and unprofitable service lines. However, with 340B purchases now comprising over 13% of drug sales, drug manufacturers argue that the program has grown beyond its original intent. They have responded to the rapid growth in contract pharmacies by enacting restrictions on distribution that in turn led to a flurry of lawsuits and legislative activity. Given the 340B program's size, importance, and role in ongoing policy debates, it is perhaps surprising that it has received little attention in economics journals. Our paper reviews the literature on the 340B program, with an eye for the gaps in this literature that economics research can help fill. In particular, economists' causal inference econometric toolkit and theoretical understanding of the role of government intervention can help improve understanding of 340B's impacts and inform policy decisions.
Subjects: 
340B
hospitals
pharmaceuticals
prescription drugs
JEL: 
I11
I18
L25
L51
Document Type: 
Working Paper

Files in This Item:
File
Size
611.16 kB





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.